Overview of Radioimmunotherapy
Author Information
Author(s): Ng DCE
Primary Institution: Department of Nuclear Medicine and PET, Singapore General Hospital
Conclusion
Radioimmunotherapy is a promising treatment for non-Hodgkin's lymphoma with good efficacy, especially for refractory cases.
Supporting Evidence
- The response rate for Y-90 ibritumomab tiuxetan was 80%, significantly higher than the 56% for single-agent rituximab.
- A Phase II trial showed a complete response rate of 32% for I-131 tositumomab.
- Long-term follow-up indicated a median time to progression of 28.3 months for patients treated with Y-90 ibritumomab tiuxetan.
Takeaway
Radioimmunotherapy uses special antibodies to deliver radiation directly to cancer cells, helping to treat certain types of blood cancers.
Methodology
The study reviewed various monoclonal antibodies and radionuclides used in radioimmunotherapy, focusing on their clinical applications and efficacy.
Potential Biases
Potential bias due to the review nature of the study and reliance on published literature.
Limitations
The study primarily focuses on non-Hodgkin's lymphoma and may not generalize to other cancers.
Participant Demographics
Patients with non-Hodgkin's lymphoma, including those who were refractory to conventional therapies.
Statistical Information
P-Value
p=.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website